Company Overview of Targazyme, Inc.
Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...
3200 County Road 104
Floresville, TX 78114
Founded in 2005
Key Executives for Targazyme, Inc.
Co-Founder, Chairman and Chief Executive Officer
Co-Founder and Vice President of Research
Senior Vice President of Regulatory Affairs & Quality Assurance
Senior Vice President of Development
Compensation as of Fiscal Year 2015.
Targazyme, Inc. Key Developments
Targazyme Collaborates with the University of Minnesota Medical Center
Nov 16 15
Targazyme has collaborated with the University of Minnesota Medical Center. It was reported that the collaboration is aimed at advancing the development of the company's clinical product candidate, TZ101 for use with regulatory T cells. It is based on positive proof of concept data published in the journal 'Blood' demonstrating that ex vivo treatment of Tregs with TZ101 prior to administration is an effective strategy for the prevention of Graft-Versus-Host-Disease. The new partnership will concentrate on improving understanding of the mechanisms involved with TZ101-treated Treg immunotherapy in the transplant and autoimmune disease settings.
Targazyme, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 02:00 PM
Oct 7 15
Targazyme, Inc. Presents at 14th Annual BIO Investor Forum, Oct-21-2015 02:00 PM. Venue: Parc 55 Hotel, San Francisco, California, United States.
Targazyme, Inc. Receives U.S. Food and Drug Administration IND Clearance for Phase I/II Study of TZ101-Treated Regulatory T Cells to Prevent Graft
Mar 17 15
Targazyme, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted IND Clearance to M.D. Anderson Cancer Center to start
enrolling patients in a Phase I/II clinical study to evaluate the safety and efficacy of TZ101-fucosylated regulatory T cells (Tregs) in preventing and reducing the severity and incidence of graft vs. host disease (GVHD) in patients eligible for hematologic stem cell transplant. GVHD is a serious, life-threating complication of stem cell transplantation, affecting over 60% of all patients undergoing allogeneic stem cell transplantation.Â This clinical study hopefully will affirm Targazyme's novel treatment approach. TZ101 could potentially transform hematopoietic stem cell transplantation by reducing patient morbidity and mortality from GVHD, which occurs in a high percentage of these patients and is very difficult to manage clinically.Â If the efficacy of TZ101-treated Tregs is demonstrated in GVHD, then the company expects the treatment to be useful in a number of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and others.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|